Form 8-K for ARIAD PHARMACEUTICALS INC
Other Events, Financial Statements and Exhibits
Item 8.01 Other Events.On March 25, 2015, ARIAD Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that the United States District Court for the District of Massachusetts dismissed the shareholder class action lawsuit filed in late 2013 against the Company and certain of its officers, directors and underwriters in connection with the events leading up to the temporary suspension of the marketing and commercial distribution of Iclusig� (ponatinib) on October 31, 2013, and subsequent re-launch in January 2014 based on revised U.S. prescribing information and a risk evaluation and mitigation strategy. A copy of the press release announcing this event has been filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
99.1 Press Release dated March 25, 2015
The press release contains hypertext links to information on our websites. The information on our websites is not incorporated by reference into this Current Report on Form 8-K and does not constitute a part of this Form 8-K.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.ARIAD Pharmaceuticals, Inc.
By: /s/ Thomas J. DesRosier Thomas J. DesRosier
Executive Vice President, Chief Legal and Administrative Officer
Date: March 25, 2015